How Tau Sabotages Brain-Cell Batteries — a New Clue to Alzheimer’s

Scientists have pinpointed a way the Alzheimer’s-linked protein tau damages brain cells: it slips inside the cell’s power plants and makes their energy machinery run in reverse.

Researchers at Stanford University School of Medicine and UCSF found that hyperphosphorylated tau — the abnormal form that builds up in Alzheimer’s — enters mitochondria and binds a component of the electron transport chain called NDUFS3. Published August 6, 2026 in Neuron.

What tau normally does

Tau’s ordinary job is structural: it stabilises microtubules, the internal scaffolding along which neurons transport cargo between the cell body and distant synapses.

Its binding is regulated by phosphorylation — attaching phosphate groups changes how tightly it holds. Some phosphorylation is normal and dynamic.

In Alzheimer’s, tau becomes excessively phosphorylated. It detaches from microtubules, which destabilises transport, and the freed protein aggregates into the tangles that are a defining feature of the disease. This finding adds a third consequence: the detached protein also goes somewhere it should not.

What reverse electron transport means

Binding NDUFS3 warps the machinery, causing reverse electron transport that spews out damaging reactive oxygen molecules.

The electron transport chain normally passes electrons through a series of complexes, using the energy released to pump protons across a membrane and ultimately to make ATP. NDUFS3 is part of Complex I, where the chain begins.

Under certain conditions electrons can flow backwards into Complex I instead of forwards. When they do, the complex generates superoxide at high rates — the reaction is a known feature of mitochondrial biochemistry, normally limited by conditions that rarely persist.

A protein locking the complex into that state would make an occasional event continuous, which is a specific and testable mechanism rather than a general claim about oxidative stress.

The self-perpetuating cycle

The reactive oxygen molecules feed a self-perpetuating cycle of injury, and the loop is what makes the mechanism plausible as a driver of progressive disease.

Oxidative stress promotes the kinase activity that hyperphosphorylates tau. More hyperphosphorylated tau enters more mitochondria, producing more reactive oxygen species, driving further phosphorylation.

Feedback of that kind explains something a linear mechanism cannot: why the disease accelerates once established, and why it continues after whatever initiated it has passed.

Why neurons are especially exposed

Neurons have unusually high and unrelenting energy demands. Maintaining ion gradients across a large membrane surface and supporting synaptic transmission consumes ATP continuously, and neurons have little capacity for anaerobic metabolism.

They also cannot be replaced. A damaged neuron accumulates injury over decades rather than being turned over, so a slow mechanism producing modest damage per unit time still reaches a threshold eventually.

Seen across many models

The team observed the effect in fruit flies, mice, human brain tissue, cultured neurons and patient-derived stem cells — and suggests the mechanism may link tau to mitochondrial dysfunction across several diseases.

That breadth matters. Reproduction across evolutionarily distant organisms indicates the interaction is fundamental rather than an artefact of one system, and human brain tissue confirms it occurs in the actual disease rather than only in models.

“This is the first demonstration of exactly what tau does inside mitochondria,” said Stanford’s Bingwei Lu.

A possible drug target

An experimental compound, CPT, prevented tau from binding NDUFS3, blocking the reverse electron flow without disrupting normal energy production — and improved behaviour in animal models.

That selectivity is the essential feature. Complex I is required for life, so a compound inhibiting it would be lethal. Blocking an abnormal protein-protein interaction while leaving normal function intact is the only viable version of this approach.

Why the field is looking past amyloid

A tau-focused mechanistic finding lands in a field that has spent decades on a different target, with results that explain the redirection.

The amyloid hypothesis held that accumulation of amyloid-beta plaques initiates the disease, and it dominated research and drug development for a long period. Many candidates cleared amyloid effectively without producing meaningful clinical benefit, and the drugs eventually approved on that basis deliver modest slowing at best, with meaningful safety burdens.

Tau has an empirical advantage the hypothesis lacked: tau pathology correlates with cognitive decline considerably better than amyloid burden does. Patients can carry extensive amyloid with intact cognition, while tau spread through the brain tracks symptoms closely.

That correlation does not establish causation either, and tau could be a marker of neuronal distress rather than its cause. What a specific molecular mechanism adds is testability — a compound blocking one defined interaction produces a clean experiment, and if preventing tau from binding NDUFS3 protects neurons, that is stronger evidence than any correlation.

It is early, preclinical work, but it points to a fresh, specific target — and one that differs from the amyloid-focused strategies that have dominated and largely disappointed. Research news, not medical advice.